Mass-Spectrometry-Based Method to Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease

Gwënaël Pottiez, Li Yang, Tessandra Stewart, Ning Song, Patrick Aro, Douglas R. Galasko, Joseph Quinn, Elaine R. Peskind, Min Shi, Jing Zhang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Alzheimer's disease (AD), the most common form of dementia, afflicts about 50 million people worldwide. Currently, AD diagnosis is primarily based on psychological evaluation and can only be confirmed post-mortem. Reliable and objective biomarkers for prognosis and diagnosis have been sought for years. Together, tau and amyloid β 1-42 (Aβ42) in cerebrospinal fluid (CSF) have been shown to provide good diagnostic sensitivity and specificity. Additionally, phosphorylated forms of tau, such as tau pS181, have also shown promising results. However, the measurement of such markers currently relies on antibody-based immunoassays that have shown variability, leading to discrepant results across laboratories. To date, mass spectrometry methods developed to evaluate CSF tau and Aβ42 are not compatible. We present in this article the development of a mass-spectrometry-based method of quantification for CSF tau and Aβ42 in parallel. The absolute concentrations of tau and Aβ42 we measured are on average 50 ng/mL (7-130 ng/mL) and 7.1 ng/mL (3-13 ng/mL), respectively. Analyses of CSF tau and Aβ42, in a cohort of patients with AD, mild cognitive impairment, and healthy controls (30 subjects), provide significant group differences evaluated with ROC curves (AUC(control-AD) and AUC(control-MCI) = 1, AUC(MCI-AD) = 0.76), with at least equivalent diagnostic utility to immunoassay measurements in the same sample set. Finally, a significant and negative correlation was found between the tau and Aβ peptides ratio and the disease severity.

Original languageEnglish (US)
Pages (from-to)1228-1238
Number of pages11
JournalJournal of Proteome Research
Volume16
Issue number3
DOIs
StatePublished - Mar 3 2017

Fingerprint

Cerebrospinal fluid
Amyloid
Mass spectrometry
Cerebrospinal Fluid
Mass Spectrometry
Alzheimer Disease
Area Under Curve
Immunoassay
Disease control
Biomarkers
ROC Curve
Dementia
tau-1 monoclonal antibody
Psychology
Sensitivity and Specificity
Peptides
Antibodies

Keywords

  • Alzheimer's disease
  • amyloid β
  • biomarker
  • cerebrospinal fluid
  • diagnosis
  • mass spectrometry
  • SRM
  • tau

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry

Cite this

Mass-Spectrometry-Based Method to Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease. / Pottiez, Gwënaël; Yang, Li; Stewart, Tessandra; Song, Ning; Aro, Patrick; Galasko, Douglas R.; Quinn, Joseph; Peskind, Elaine R.; Shi, Min; Zhang, Jing.

In: Journal of Proteome Research, Vol. 16, No. 3, 03.03.2017, p. 1228-1238.

Research output: Contribution to journalArticle

Pottiez, Gwënaël ; Yang, Li ; Stewart, Tessandra ; Song, Ning ; Aro, Patrick ; Galasko, Douglas R. ; Quinn, Joseph ; Peskind, Elaine R. ; Shi, Min ; Zhang, Jing. / Mass-Spectrometry-Based Method to Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease. In: Journal of Proteome Research. 2017 ; Vol. 16, No. 3. pp. 1228-1238.
@article{a295baca824e4feaaf9c2b1326fb956d,
title = "Mass-Spectrometry-Based Method to Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease",
abstract = "Alzheimer's disease (AD), the most common form of dementia, afflicts about 50 million people worldwide. Currently, AD diagnosis is primarily based on psychological evaluation and can only be confirmed post-mortem. Reliable and objective biomarkers for prognosis and diagnosis have been sought for years. Together, tau and amyloid β 1-42 (Aβ42) in cerebrospinal fluid (CSF) have been shown to provide good diagnostic sensitivity and specificity. Additionally, phosphorylated forms of tau, such as tau pS181, have also shown promising results. However, the measurement of such markers currently relies on antibody-based immunoassays that have shown variability, leading to discrepant results across laboratories. To date, mass spectrometry methods developed to evaluate CSF tau and Aβ42 are not compatible. We present in this article the development of a mass-spectrometry-based method of quantification for CSF tau and Aβ42 in parallel. The absolute concentrations of tau and Aβ42 we measured are on average 50 ng/mL (7-130 ng/mL) and 7.1 ng/mL (3-13 ng/mL), respectively. Analyses of CSF tau and Aβ42, in a cohort of patients with AD, mild cognitive impairment, and healthy controls (30 subjects), provide significant group differences evaluated with ROC curves (AUC(control-AD) and AUC(control-MCI) = 1, AUC(MCI-AD) = 0.76), with at least equivalent diagnostic utility to immunoassay measurements in the same sample set. Finally, a significant and negative correlation was found between the tau and Aβ peptides ratio and the disease severity.",
keywords = "Alzheimer's disease, amyloid β, Aβ, biomarker, cerebrospinal fluid, diagnosis, mass spectrometry, SRM, tau",
author = "Gw{\"e}na{\"e}l Pottiez and Li Yang and Tessandra Stewart and Ning Song and Patrick Aro and Galasko, {Douglas R.} and Joseph Quinn and Peskind, {Elaine R.} and Min Shi and Jing Zhang",
year = "2017",
month = "3",
day = "3",
doi = "10.1021/acs.jproteome.6b00829",
language = "English (US)",
volume = "16",
pages = "1228--1238",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Mass-Spectrometry-Based Method to Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease

AU - Pottiez, Gwënaël

AU - Yang, Li

AU - Stewart, Tessandra

AU - Song, Ning

AU - Aro, Patrick

AU - Galasko, Douglas R.

AU - Quinn, Joseph

AU - Peskind, Elaine R.

AU - Shi, Min

AU - Zhang, Jing

PY - 2017/3/3

Y1 - 2017/3/3

N2 - Alzheimer's disease (AD), the most common form of dementia, afflicts about 50 million people worldwide. Currently, AD diagnosis is primarily based on psychological evaluation and can only be confirmed post-mortem. Reliable and objective biomarkers for prognosis and diagnosis have been sought for years. Together, tau and amyloid β 1-42 (Aβ42) in cerebrospinal fluid (CSF) have been shown to provide good diagnostic sensitivity and specificity. Additionally, phosphorylated forms of tau, such as tau pS181, have also shown promising results. However, the measurement of such markers currently relies on antibody-based immunoassays that have shown variability, leading to discrepant results across laboratories. To date, mass spectrometry methods developed to evaluate CSF tau and Aβ42 are not compatible. We present in this article the development of a mass-spectrometry-based method of quantification for CSF tau and Aβ42 in parallel. The absolute concentrations of tau and Aβ42 we measured are on average 50 ng/mL (7-130 ng/mL) and 7.1 ng/mL (3-13 ng/mL), respectively. Analyses of CSF tau and Aβ42, in a cohort of patients with AD, mild cognitive impairment, and healthy controls (30 subjects), provide significant group differences evaluated with ROC curves (AUC(control-AD) and AUC(control-MCI) = 1, AUC(MCI-AD) = 0.76), with at least equivalent diagnostic utility to immunoassay measurements in the same sample set. Finally, a significant and negative correlation was found between the tau and Aβ peptides ratio and the disease severity.

AB - Alzheimer's disease (AD), the most common form of dementia, afflicts about 50 million people worldwide. Currently, AD diagnosis is primarily based on psychological evaluation and can only be confirmed post-mortem. Reliable and objective biomarkers for prognosis and diagnosis have been sought for years. Together, tau and amyloid β 1-42 (Aβ42) in cerebrospinal fluid (CSF) have been shown to provide good diagnostic sensitivity and specificity. Additionally, phosphorylated forms of tau, such as tau pS181, have also shown promising results. However, the measurement of such markers currently relies on antibody-based immunoassays that have shown variability, leading to discrepant results across laboratories. To date, mass spectrometry methods developed to evaluate CSF tau and Aβ42 are not compatible. We present in this article the development of a mass-spectrometry-based method of quantification for CSF tau and Aβ42 in parallel. The absolute concentrations of tau and Aβ42 we measured are on average 50 ng/mL (7-130 ng/mL) and 7.1 ng/mL (3-13 ng/mL), respectively. Analyses of CSF tau and Aβ42, in a cohort of patients with AD, mild cognitive impairment, and healthy controls (30 subjects), provide significant group differences evaluated with ROC curves (AUC(control-AD) and AUC(control-MCI) = 1, AUC(MCI-AD) = 0.76), with at least equivalent diagnostic utility to immunoassay measurements in the same sample set. Finally, a significant and negative correlation was found between the tau and Aβ peptides ratio and the disease severity.

KW - Alzheimer's disease

KW - amyloid β

KW - Aβ

KW - biomarker

KW - cerebrospinal fluid

KW - diagnosis

KW - mass spectrometry

KW - SRM

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=85014722120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014722120&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.6b00829

DO - 10.1021/acs.jproteome.6b00829

M3 - Article

C2 - 28112948

AN - SCOPUS:85014722120

VL - 16

SP - 1228

EP - 1238

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 3

ER -